This year’s edition of the Benzinga Psychedelics Capital Conference, THE place to be for those interested or already involved in the space, will take place on April 13, following our established Cannabis Capital Confere
The upcoming Psychedelics Capital Conference constitutes Benzinga’s effort to provide an exclusive opportunity to meet, connect with and learn from some of the most knowledgeable people in the space.
Psychedelics Bills Around The Country: 9 New Proposals, Several Passes, Several Fails And A Successful Local Decriminalization
Throughout the 2023 session, numerous discussions have been held and various measures have been considered around the legalization of psychedelics.
Let’s go over the latest proposed regulations.
This year is the second edition of what is rapidly becoming the place to be for those interested in or already involved in the psychedelics space: new deals get closed, money gets raised and knowledge is shared at this not-to-be-missed gathering for investors, key partners as well as the general public.
The clinical-stage biopharma company atai Life Sciences (NASDAQ: ATAI) founded in 2018 shared updates on the two clinical trials as well as its plan to streamline its workforce with significant layoffs.
After everything that's happened in the last several years, we believe it's safe to say that the psychedelic renaissance is a reality, one that Benzinga has consistently reported on.
Adastra Labs Ltd. (OTCPK:XTXXF) (CSE:XTRX) (FRA:D2EP) provided clarification regarding its receipt of Health Canada approval for the amendment to include cocaine under its controlled substances license.
“Marijuana is different, that actually really did help me,” Prince Harry told physician and author Dr. Gabor Maté on Saturday in a widely viewed live-stream interview about the importance of personal healing.
Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL), a pharmaceutical company developing proprietary medicinal cannabinoid products and psychedelic medicine therapies for unmet medical needs, has engaged Catalent (NYSE: